Format

Send to

Choose Destination
See comment in PubMed Commons below
Eur J Cancer Prev. 2012 Mar;21(2):171-81. doi: 10.1097/CEJ.0b013e32834c9c26.

Prevention of ER-negative breast cancer: where do we stand?

Author information

1
Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy. massimiliano.cazzaniga@ieo.it

Abstract

Oestrogen receptor-negative and triple-negative breast cancers are types of aggressive tumours that account for approximately 30 and 15% of total breast cancers, respectively. Selective oestrogen receptor modulators and aromatase inhibitors are unable to treat and prevent these subtypes of mammary tumours. Thus, it is worth identifying new pathways, biomarkers, and agents that are effective in the treatment and prevention of these subtypes. Several classes of drugs have been studied, and many are still currently under investigation. We have attempted to conduct a state-of-the-art study on this important issue.

PMID:
21968686
DOI:
10.1097/CEJ.0b013e32834c9c26
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wolters Kluwer
    Loading ...
    Support Center